Thus, the blocking of IL-1 with IL-1 receptor antagonist is reported to protect animals from lethal endotoxemia and Gram-negative sepsis [9] and patients from proven bacteremia [48]. Here, IL1B is linked to serum lipopolysaccharide activity.